DOI: 10.55522/jmpas.V14I1.6786 **ISSN NO. 2320 – 7418**

International peer reviewed open access journal

Journal of Medical Pharmaceutical and Allied Sciences

Journal homepage: www.jmpas.com CODEN: JMPACO

Review article

Quintessence study on the scrutinize treatment of rheumatoid arthritis by monoclonal antibodies manoeuvres

SS Pravin*, M Mohana Krishna, R Kavitha

SRM College of Pharmacy, SRM Institute of Scienceand Technology, Kattankulathur, Chengalpattu, Tamil Nadu, India

Corresponding author: SS Pravin, ✉ ps3021@srmist.edu.in, **Orcid Id**: https://orcid.org/0009-0006-5104-6529

SRM College of Pharmacy, SRM Institute of Scienceand Technology, Kattankulathur, Chengalpattu, Tamil Nadu, India

Received - 11-09-2024**, Revised** - 27-01-2025, **Accepted** - 12-02-2025 **(DD-MM-YYYY)**

Refer This Article

SS Pravin, M Mohana Krishna, R Kavitha, 2025. Quintessence study on the scrutinize treatment of rheumatoid arthritis by monoclonal antibodies manoeuvres. Journal of medical pharmaceutical and allied sciences, V14 - I 1, Pages - 6982 – 6987. Doi: https://doi.org/10.55522/jmpas.V14I1.6786.

ABSTRACT

In a standard pathology lab or when it aids in clinical diagnosis and patient care, monoclonal antibodies act effectively. In order to provide a better understanding and provide a therapeutic strategy for rheumatoid arthritis, the synthesis and applications of monoclonal antibodies are discussed in this article. A monoclonal antibody therapy targets foreign substances that are damaging to the body and imitates the immune system's normal reaction. In both contemporary and future medical practice, monoclonal antibodies represent a potent kind of therapy. There are different types of monoclonal antibodies which are Murine, secondly the Chimeric, thirdly Humanized, Human. A monoclonal antibody that targets the pathogenic cytokine and cellular components present in the RA synovium is the most common type of biologic created to date. All of the immune cells are clones of a single parent cell, known as immune cells, create monoclonal antibodies (mAbs), which are monospecific antibodies. Anti-CD4, anti-CD7, and CAMPATH-1H were the goals of the initial research utilizing mAbs in RA, with various degrees of effectiveness and serious safety issues. However, the US FDA has approved the use of polyspecific mAbs that are directed against a variety of distinct target molecules for the medical intervention of RA. These include TNF-α, B cells that are CD20-positive, IL-1, and IL-6. Etanercept and Abatacept are two more biological medicines that have been authorized for the treatment of RA; they are fusion proteins rather than monoclonal antibodies.



Remarkable advancements were achieved that made it possible to manufacture antibodies with altered molecular characteristics, such valence., terms of size, precision, and propensity. The half-life of serum and mechanism of effect can also be further tuned thanks to advances in antibody engineering technology. In order to get meaningful results from systemic therapy and prevent adverse side effects, optimal distribution to the intended tissue must still be dealt with.

Keywords: Monoclonal antibody, Mouse monoclonal antibodies, Synovim, Rheumatoid arthritis, Hybridoma cells.

INTRODUCTION

Antibodies: What are they? We fight infections with the aid of molecules known as antibodies, which are found in homeostatic bodily fluids. Although the fundamental structure of an antibody is generally "Y" composed of the two spots intended to identify and attach (fig. 1) foreign agents (for instance, bacteria), foreign chemicals, or dangerous cells, there are numerous molecules of antibodies of various sizes and forms [1].

Figure 1: Structure of an Antibody



For many molecular immunology research, monoclonal antibodies are crucial tools. When paired with techniques like molecular modelling and epitope mapping, monoclonal antibodies in particular make it possible to image macromolecular surfaces and perform antigenic profiling [2]. Additionally, monoclonal antibodies have evolved into crucial components of several clinical laboratory diagnostic tests [3]. The extraordinary specificity of these unique reagents has led to their widespread usage in the detection and differentiation of pathogenic microorganisms, cell markers, and serum analytes [4]. Additionally, a continuous growth of the hybridoma cells [5]. Used to manufacture these antibodies outperforms the promise of an endless reagent supply [6]. In essence, The capacity to possess a continuous providing of reagents permits the polyclonal antibody and the reagent to be standardized due to the relatively restricted supply of both materials and the field of monoclonal antibody development provides an important avenue like targeting of particular mutation site and targeting the faulty region in specific protein structure, as well as in ex in most of the illness and condition [7, 8]. The first monoclonal antibody was officially licenced in 1986. Recent major advancements in genetic sequencing have made humanized monoclonal antibodies are the fastest-growing class of biotechnology-derived medicines in clinical trials and the clinical application of research in the fundamental medical sciences. The market for antibodies is estimated to be about $20 billion annually on a worldwide scale. Currently, the FDA has approved the use of about 30 monoclonal antibodies in humans to cure a range of ailments and disorders, like cancer , chronic inflammatory illnesses, transplantation, infectious diseases, and cardiovascular. This is especially evident when a monoclonal antibody aids in clinical diagnosis and patient care, or when it works well in a standard pathology lab. In order to provide a better understanding and provide a therapeutic strategy for rheumatoid arthritis, the synthesis and applications of monoclonal antibodies are discussed in this article [9].

Monoclonal Antibodies

An antibody is a naturally occurring, Y-shaped protein that the immune system of our bodies produces to target something that is foreign or not a part of the body. These foreign bodies, also known as antigens, can be found on allergens, bacteria, viruses, as well as other things like toxins or an organ transplant [10, 11].

Monoclonal antibody therapy targets foreign substances that are damaging to the body and imitates the immune system's normal reaction. In both contemporary and future medical practice, monoclonal antibodies represent a potent kind of therapy. Monoclonal antibodies are a crucial tool utilized in the study of biomedicine, disease diagnostics, & treatment for cancer and other illnesses. The cell lines are produced by fusing myeloma cells with B cells from the immunized animal (Köhler and Milstein 1975). The cells must be generated in one of two ways: either by tissue culture in vitro or through injection into the peritoneal cavity of a ready-made animal (the in vivo, or mouse ascites, approach) [12, 13].

Monoclonal Antibody Types

Manufactured by humans in the immune system, monoclonal antibodies work similarly to human antibodies. They may be made in four different ways, and the name of each method depends on the material used to make it [14, 15].

Murine

These drugs terminate in -omab and are synthesised from mouse proteins.

Chimeric

These proteins are a combination of human and mouse components, and the names of the drugs end in – ximab [16, 17].

Humanized

The drugs are made from small mouse protein fragments attached to human proteins, and their names end in -zumab.

Human

These proteins are all human, and the therapeutic names end in –umab [18, 19].

Monoclonal Antibodies towards the Treatment of the Rheumatoid Arthritis Manoeuvre

The treatment of rheumatoid arthritis (RA) has changed significantly since the introduction of biological therapies 10 years ago. It is now feasible to achieve remission in the clinical, functional, and radiological domains. Recent advancements in the treatment of RA have depended heavily on clinical research employing biologic medicines. A monoclonal antibody that targets the pathogenic cytokine and cellular components present in the RA Synovim is the most common type of biologic created to date. Antibodies known as monoclonal antibodies (mAbs) 21 are nonspecific antibodies produced by immune cells that are all clones of a single parent cell. The first studies using mAbs in RA focused on anti-CD4, anti-CD7, and CAMPATH-1H, with varying degrees of efficacy and significant safety concerns. But for the treatment of RA, the US FDA has authorized the use of polyspecific mAbs that target many different target molecules. These are, TNF-α, CD20-positive B cells, IL-1 and IL-6 [20, 21].

Etanercept and Abatacept are two more biological medicines that have been authorized for the treatment of RA; they are fusion proteins rather than monoclonal antibodies. (Proteomics) [22, 23].

Monoclonal Antibodies Directed Against Tnf-A

The inflammation-induced joint destruction that is a major contributing factor to RA is mediated in large part by TNF. TNF-induced immunological responses, such as the synthesis of matrix metalloproteinase, cytokines, and adhesion molecules, neutrophil activity, dendritic cell function, and osteoclast development, are suppressed by monoclonal antibodies to TNF that bind soluble and transmembrane TNF. In the presence of complement, TNF-expressing cells can be lysed by monoclonal antibodies against TNF. It has been used often and widely to lower TNF- levels, which in turn lowers RA indications and symptoms. There are now four mAbs that are authorized to treat RA [24, 25].

Infliximab

A chimeric IgG1 mAb called infliximab has murine variable regions and human constant regions. It should be used with methotrexate and is only accessible in intravenous form (MTX). Starting at 3 mg/kg, the dosage can be increased to 10 mg/kg with a 4-to-8-week gap between treatments [26, 27].

Adalimumab

A human recombinant IgG1 mAb is called Adalimumab made using phage display technique and is free of any murine material. In 2002, the FDA and EMA granted it a license or shortly thereafter in order to treat mild serious RA as a monotherapy or in conjunction with medications that treat rheumatoid arthritis (DMARDs). A dosage of 40 mg administered subcutaneously every two weeks is available [28, 29].

Golimumab

A completely human IgG1 anti-TNF antibody known as golimumab was produced and affinity matured in an in vivo system. Without the mouse protein, it has a structure that is extremely similar to infliximab. In conjunction with MTX, it was given FDA/EMA approval in 2009 or shortly afterwards for the treatment of moderate-to-severe RA. The 50 mg once-monthly subcutaneous form is authorized, and although an intravenous formulation has also been developed, it is still in the pre-clinical testing stage [30, 31].

Certolizumab

Certolizumab pegol is a polyethylene glycol (PEG) moiety35 that has been bonded to a humanized Fab fragment (Fc free). The goal of PEGylation was to enhance absorption, pharmacodynamics, and maybe localization to inflammatory tissues. Fc-mediated effects such complement-dependent cytotoxicity and antibody- dependent cytotoxicity are reduced when an Fc region is absent36. In 2009, it received FDA/EMA approval to treat moderate-to-severe RA either alone or in conjunction with MTX37. 400 mg at 0, 2, and 4 weeks, then every 2 weeks, or 400 mg every 4 weeks, is the subcutaneous dosage that is offered [31].

Monoclonal Antibodies Directed Against Cd20

Rituximab is a monoclonal antibody (mAb) that depletes B lymphocytes and is utilized as a therapeutic biologic agent in rheumatoid arthritis (RA), as well as other autoimmune diseases and lymph proliferative disorders. It targets the CD20 antigen. Rituximab is regarded as a biologic disease-modifying ant rheumatic medication (DMARD) among treatments for RA since it can lessen disease signs and symptoms and slow the course of joint damage. The majority of the side effects of rituximab, such as infusion reactions, decreased immunoglobulin levels, and an increased risk of specific infections, are caused by the immune system activation that is caused by the drug to deplete B cells, as well as its immunogenicity and immunosuppressive properties. Rituximab is an immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that is hypothesized to work largely by eliminating CD20-positive B cells from the body. CD20 is a type of protein found on the external side of most B cells. It is hybrid antibody made up of mouse and human parts. Depletion of B cells also seems to have long lasting impacts on immune cell performance on the enamel surfaces after remineralization [32].

Figure 1: Molecular Mechanisms and Treatment of Rheumatoid Arthritis



Antibodies That Interfere With Il-6 Function

A variety of immunologically significant cells generate the pleotropic cytokine IL-6, which is crucial for the activation of T cells and the release of immunoglobulin [35, 36]. Additionally, it promotes osteoclast activation and fibroblast differentiation in Synovim. Many of the widespread systemic consequences of RA, such as chronic illness-related anemia and the acute phase reactants observed in this disease, are also, in part, caused by dysregulation of IL-6. Tocilizumab, also MRA is an IgG1 humanized monoclonal antibody that targets the soluble and transmembrane versions of the IL-6 receptor [37].It is the most widely used monoclonal antibody. It was authorized by the FDA/EMA with a monthly intravenous dose of 4 and 8 mg/kg for the treatment of moderate-to-severe RA in patients who do not respond adequately to DMARDs and/or anti- TNF in early 2010, or just before. Currently being researched is tocilizumab in a subcutaneous version [38, 39].

Antibodies That Interfere with IL-1 Function

Multiple immunologic and inflammatory pathways are mediated by IL-1, which is generated by a variety of cell types in response to various inflammatory stimuli. The endogenous production in the Synovim, an IL-1 receptor antagonist is likely to be inadequate in RA patients to offset the elevated amounts of IL-1 generated by this condition. The FDA/EMA authorized anakinra, a recombinant version of a human receptor antagonist (IL-1ra), in 2002 or shortly afterwards treating moderate-to-severe RA at a subcutaneous dosage of 100 mg per day [40].

Future Perspective

Today, there are several medications as a curative for RA, many of which are monoclonal antibodies. A number of brand-new monoclonal antibodies are now being created, and perhaps they will soon be offered as substitutes. The optimal way to employ each of the currently available agents will hopefully be determined by research in the future that take into account cost, effectiveness, and safety with fewer or different agents employed for maintenance, they may Eventually be utilised in aggressive induction combination procedures [41]. Ideally, a biomarker calculation will also be able to determine which patients should receive the most aggressive treatment and which ones shouldn't. Future research is required on a number of topics [42]. including choosing the best medications for specific individuals and figuring out whether therapy should be continuous or intermittent. Although there are a number of crucial difficulties that will need to be overcome through properly planned and evaluated clinical research, the future of RA therapy looks to be full of promise [43].

CONCLUSION

Since Kohler and Milstein published their initial study on the hybridoma-based synthesis monoclonal antibodies (mAbs) in mice, mAbs have a significant influence on treatment by offering an essentially infinite reservoir of diagnostic instruments and therapies. Treatments for many disorders, including transplanting, cancer, Infectious, cardiovascular, and autoimmune disorders, now frequently include the therapeutic use of mAbs. By swapping out the sequences of the murine for their human equivalent, the immunogenicity restriction of murine mAbs was removed, enabling the synthesis of chimeric, humanized, and human therapeutic antibodies. Following the introduction of display technologies, remarkable advancements were achieved that made it possible to manufacture antibodies with altered molecular characteristics, such as size, affinity, specificity, and valiancy. The effector function and serum half-life can also be further tuned thanks to advances in antibody engineering technology. In order to get meaningful results from systemic therapy and prevent adverse side effects, optimal distribution to the intended tissue must remain to be dealt with.

REFERENCES

1. J Campbell, D Lowe, M A Sleeman, 2011. Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis. Br J Pharmacol. 162(7), Pages 1470–1484. Doi: 10.1111/j.1476-5381.2010.01183.x.

2. D Banker, 2001. Monoclonal antibodies. A review. Indian J Med Sci. 55(12), Pages 651–654. Doi: 10.2174/1574884712666170809124728.

3. M M Soliman, K L Hyrich, M Lunt, et al, 2012. Effectiveness of rituximab in patients with rheumatoid arthritis: Observational study from the British society for rheumatology biologics register. Journal of Rheumatology. 39(2), pp.Pages 240 – 246. Doi: 10.3899/jrheum.110610.

4. J Askling, 2005. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 64(10), Pages 1421–1426. Doi: 10.1136/ard.2004.033993.

5. E Choy, G Kingsley, S Panayi, 1998. Monoclonal antibody therapy in rheumatoid arthritis. Br J Rheumatol. 37(5), Pages 484– 490. Doi: 10.1093/rheumatology/37.5.484.

6. J Posner, P Barrington, T Brier, 2019. Monoclonal antibodies: Past, present and future in Handbook of Experimental Pharmacology. 260, Pages 81–141. Doi: 10.1007/164_2019_323.

7. L Van Hoecke, K Roose, 2019. How mRNA therapeutics are entering the monoclonal antibody field. BioMed Central Ltd. Doi: 10.1186/s12967-019-1804-8.

8. L Hood, J Davie, 1980. Antibody Diversity Patterns and Structure of Idiotypic Determinants on Murine Anti- α (1 → 3) Dextran Antibodies. Monoclonal Antibodies. Pages 37–48. Doi: 10.1007/978-1-4615-7505-4_3.

9. K Denis, R Kennett, N Klinman, 2009. Defining the B-Cell Repertoire with Hybridomas Derived from Monoclonal Fragment Cultures. Monoclonal Antibodies. Pages 49–59. Doi: 10.1007/978-1-4615-7505-4_4.

10. G Loudos, 2012. Molecular Nanomedicine towards Cancer. J Pharm Sci. 101(7), Pages 2271– 2280. Doi: 10.1002/jps.

11. H Hengartner, T Meo, E Müller, 1980. The Use of Hybridomas to Localize Mouse Immunoglobulin Genes. Monoclonal Antibodies. Pages 61–71. Doi: 10.1007/978-1-4615-7505-4_5.

12. T Hansel, H Kropshofer, T Singer, 2010. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 9(4), Pages 325–338. Doi: 10.1038/nrd3003.

13. L E Millikan, J A Witkowski, L C Parish, 1984. Monoclonal Antibodies. Int J Dermatol. 23(5), Pages 318–319. Doi: 10.1111/j.1365- 4362.1984.tb04059.x.

14. L De Rycke, 2004. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: Diagnosis value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis. 63(12), Pages 1587–1593. Doi: 10.1136/ard.2003.017574.

15. D M Ecker, S D Jones, H L Levine, 2015. The therapeutic monoclonal antibody market. MAbs. 7(1), Pages 9–14. Doi: 10.4161/19420862.2015.989042.

16. V R Zurawski, P H Black, E Haber, 1980. Continuously Proliferating Human Cell Lines Synthesizing Antibody of Predetermined Specificity. Monoclonal Antibodies. Pages 19–33, 1980, doi: 10.1007/978-1-4615-7505-4_2.

17. W G Carlos, 2021. Monoclonal antibodies: Medical uses for the prevention and treatment of disease. Am J Respir Crit Care Med. 203(11), Pages 26–27. Doi: 10.1164/rccm.2021C3.

18. F Wolfe, K Michaud, 2007. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum. 56(9), Pages 2886–2895, Doi: 10.1002/art.22864.

19. S Lim, K Kim, C Choi, 2022. Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis. J Pers Med. 12(8), Doi: 10.3390/jpm12081265.

20. E. M. Erin et al., "Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists," Eur J Immunol, vol. 174, no. 12, pp. 753–762, 1990, doi: 10.1164/rccm.200601-072OC.

21. M A Lopez-Olivo, 2012. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: A meta-analysis. JAMA. 308(9), Pages 898–908. Doi: 10.1001/2012.jama.10857.

22. F C Breedveld, 2003. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis. 63(2), Pages 149–155, Doi: 10.1136/ard.2003.013961.

23. A Cheifetz, 2003. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 98, Pages 1315–1324. Doi: 10.1016/s00029270(03)00231-4.

24. A C Mackey, L Green, L C Liang, et al, 2007. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 44(2), Pages 265–267. Doi: 10.1097/MPG.0b013e31802f6424.

25. M Svenson, P Geborek, T Saxne, 2007. Monitoring patients treated with anti- TNF-α biopharmaceuticals: Assessing serum infliximab and anti-infliximab antibodies. Rheumatology. 46(12), Pages 1828–1834. Doi: 10.1093/rheumatology/kem261.

26. M Cohen, M A Omair, E C Keystone, 2013. Monoclonal antibodies in rheumatoid arthritis. Int J Clin Rheumtol. 8(5), Pages 541–556. Doi: 10.2217/ijr.13.52.

27. P J Mease, P J Mease, 2007. Therapeutics and Clinical Risk Management Adalimumab in the treatment of arthritis Ther Clin Risk Mana. 3(1), Pages 133-48. Doi: 10.2147/tcrm.s31133.

28. N Scheinfeld, 2005. Adalimumab: A review of side effects. Expert Opin Drug Saf. 4, Pages 637–641. Doi: 10.1517/14740338.4.4.637.

29. B H Thiers, 2009. Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis. Yearbook of Dermatology and Dermatologic Surgery. 2009, Pages 244–245. Doi: 10.1016/s0093-3619(08)79186-x.

30. E C Keystone, 2009. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study. Ann Rheum Dis. 68(6), Pages 789–796. Doi: 10.1136/ard.2008.099010.

31. R Taylor, A Lindorfer, 2008. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol. 4, Pages 444–449. Doi: 10.1016/j.coi.2008.05.011.

32. R Bruno, D Combs, B Davies 2005. Population pharmacokinetics of rituximab (anti- CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 45(7), Pages 792–801. Doi: 10.1177/0091270005277075.

33. M J Glennie, R R French, M S Cragg, 2007. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 44(16), Pages 3823–3837. Doi: 10.1016/j.molimm.2007.06.151.

34. M Diamant, K Bendtzen, 1995. Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors. Eur J Immunol. 25(2), Pages 348–354. Doi: 10.1002/eji.1830250207.

35. M Lyman, 2018. A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases. Journal of Biological Chemistry. 293(24), Pages 9326–9334. Doi: 10.1074/jbc.M117.818559.

36. S Kang, T Tanaka, 2008. T Kishimoto, Therapeutic uses of anti-interleukin-6 receptor antibody. Int Immunol. 27(1), Pages 21–29. Doi: 10.1093/intimm/dxu081.

37. S C Jordan, 2006. Interleukin-6, A cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: Therapeutic implications of IL-6 receptor blockade. Transplantation. 101, Pages 32–44. Doi: 10.1097/TP.0000000000001452.

38. J Liautard, 1997. Specific inhibition of IL-6 signalling with monoclonal antibodies against the gp130 receptor. Cytokine. 4, Pages 233–241. Doi: 10.1006/cyto.1996.0159.

39. M Mihara, 2005. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 5, Pages 1731–1740. Doi:10.1016/j.intimp.2005.05.010.

40. G Jones, 2010. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis. 69(1), Pages 88–96. Doi: 10.1136/ard.2008.105197.

41. P Emery, 2008. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti- tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 67(11), Pages 1516–1523. Doi: 10.1136/ard.2008.092932.

42. K Tsumoto, Y Isozaki, H Yagami, 2019. Future perspectives of therapeutic monoclonal antibodies. Immunotherapy. 11(2), Pages 119–127. Doi: 10.2217/imt-2018-0130.

43. E M Sánchez-Robles, R Girón, N Paniagua, et al, 2021. Monoclonal antibodies for chronic pain treatment: Present and future. Int J Mol Sci. 22(19), Pages 1–26. Doi: 10.3390/ijms221910325.